Top Markets
#1 Zora Zora +31.42%
#2 SSV Network SSV Network +23.75%
#3 Arowana Arowana +23.56%
#4 Pieverse Pieverse +23.14%
#5 Fabric Protocol Fabric Protocol +22.66%
#6 EXOD EXOD +22.08%
#7 Backpack Backpack +22.06%
#8 The Black Bull The Black Bull +21.96%
#9 GALA GALA +21.77%
#10 Velvet Velvet +21.75%
Coin of the day
Zora Zora
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Orexo AB Orexo AB

Orexo AB

ORX
Clasificación en acciones #24896
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Precio por acción
$1.58
Capitalización bursátil
$55.40M
Cambio (1 día)
0.71%
Cambio (1 año)
-28.43%
País
SE
Comercio Orexo AB (ORX)

Categoría

Healthcare
Ganancias de Orexo AB (ORX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Orexo AB, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Orexo AB desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
$26.37M -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
$992.42M -
HK